Harding v. Cordis Corp. , 2021 IL App (1st) 210032 ( 2021 )


Menu:
  •                                      
    2021 IL App (1st) 210032
    SIXTH DIVISION
    December 3, 2021
    IN THE
    APPELLATE COURT OF ILLINOIS
    FIRST DISTRICT
    No. 1-21-0032
    PATTIE A. HARDING,                                )
    )                   Appeal from the
    Plaintiff-Appellee,                        )                   Circuit Court of
    )                   Cook County.
    v.                                                )
    )
    CORDIS CORPORATION, a Florida Corporation;        )
    JOHNSON & JOHNSON, a New Jersey Corporation;      )                   No. 17 L 8306
    CONFLUENT MEDICAL TECHNOLOGIES, INC., a           )
    Delaware Corporation; and GAIL SUSAN SMITH, M.D., )
    )
    Defendants,                                )                   The Honorable
    )                   Gerald Cleary,
    (Confluent Medical Technologies, Inc., Defendant- )                   Judge Presiding.
    Appellant).                                       )
    JUSTICE MIKVA delivered the judgment of the court, with opinion.
    Presiding Justice Pierce and Justice Oden Johnson concurred in the judgment and opinion.
    OPINION
    ¶1     The question before us is whether a defendant who manufactures a custom component of
    a medical device that is alleged to have caused injury to an Illinois resident has sufficient minimum
    contacts with this state to subject itself to the jurisdiction of our courts. This defendant knew the
    medical device was sold in the United States but not which specific states it was sold in. The
    defendant also sold other similar products directly to Illinois. We hold that our courts do have
    jurisdiction over this defendant for the reasons outlined in this opinion.
    No. 1-21-0032
    ¶2      The plaintiff, Pattie A. Harding, brought a suit against several defendants, including
    Confluent Medical Technologies, Inc. (Confluent), after suffering injuries due to what she alleged
    was a defective medical device manufactured, sold, and implanted by the defendants. Confluent
    moved, unsuccessfully, to dismiss the claims against it for a lack of personal jurisdiction.
    Confluent now appeals, arguing that it lacks the requisite minimum contacts with Illinois for the
    State to exercise personal jurisdiction over it. For the following reasons, we affirm.
    ¶3                                       I. BACKGROUND
    ¶4      Ms. Harding alleged in her complaint that in June 2010 she suffered personal injuries as a
    direct and proximate result of a defective inferior vena cava (IVC) filter. According to the
    complaint, an IVC filter is a medical device “designed to filter or ‘catch’ blood clots that travel
    from the extremities to the heart and lungs.” Computerized tomography scans performed in
    December 2015 and February 2016 revealed that “tines” of the IVC filter had perforated the wall
    of Ms. Harding’s inferior vena cava, that the filter had migrated and fractured, and that a piece of
    the filter was lodged in Ms. Harding’s heart.
    ¶5      Ms. Harding alleged that Confluent was incorporated in Delaware and headquartered in
    California. She further alleged that Confluent was an affiliate of Cordis Corporation (Cordis) and
    was involved in the manufacture and design of the IVC filters. Ms. Harding alleged that “Confluent
    ha[d] conducted business and derived substantial revenue from within the State of Illinois, from
    including, but not limited to, its business activities related to [the] IVC filters.”
    ¶6      Ms. Harding also alleged that Confluent and Cordis:
    “were engaged in the business of researching, developing, designing, setting specifications
    for, licensing, manufacturing, preparing, compounding, assembling, processing, selling,
    distributing, marketing, and/or introducing into interstate commerce and into the State of
    -2-
    No. 1-21-0032
    Illinois, either directly or indirectly through third parties or related entities, the Cordis IVC
    filters—specifically, the OptEase filter—to be implanted in patients throughout the United
    States, including Illinois, and including the Cordis IVC filters implanted in [Ms. Harding],
    and derived substantial income from doing business in Illinois.”
    ¶7      Ms. Harding also states in her brief that “[t]he OptEase IVC filter medical device was
    comprised of the nitinol filter manufactured by Confluent, the delivery system, instructions for
    use, and other labeling materials,” suggesting that the nitinol filter custom manufactured by
    Confluent for Cordis was the significant component of Cordis’s OptEase filter. Confluent did not
    refute this characterization of its product.
    ¶8      Ms. Harding’s claims against Confluent and Cordis included strict products liability based
    on a product defect, an inadequate warning, and a manufacturing defect; negligence; negligent
    misrepresentation; fraudulent misrepresentation; fraudulent concealment; and breaches of both
    express warranty and implied warranty of merchantability. She asked for general noneconomic
    damages for past and future pain and suffering, emotional distress, and loss of enjoyment of life,
    plus special economic damages for past and future medical expenses, disgorgement of profits,
    restitution, statutory damages, costs, and pre- and post-judgment interest.
    ¶9      Confluent moved to dismiss Ms. Harding’s complaint under sections 2-301 and 2-619 of
    the Code of Civil Procedure (Code) (735 ILCS 5/2-301, 2-619 (West 2018)). It argued that Ms.
    Harding had failed to allege any facts that would allow the circuit court to exercise personal
    jurisdiction over it. Confluent stated that it “did not design, manufacture, market, sell or distribute
    any portion of the OptEase IVC filter at issue in this case in Illinois” and that Ms. Harding therefore
    could not show that Confluent “purposefully directed its activities at Illinois” or that the claims
    against Confluent “arose out of or relate[d] to Confluent’s contacts with Illinois.”
    -3-
    No. 1-21-0032
    ¶ 10    Confluent explained that, although it did manufacture nitinol component parts used in
    Cordis’s OptEase filter, “using the manufacturing processes from Cordis and based on the design
    and specifications from Cordis,” it did so in California until 2010 and thereafter in Costa Rica.
    According to Confluent, it “sells the component parts directly to Cordis and ships them to Juarez,
    Mexico.” Confluent maintained that it did not sell, distribute, or manufacture nitinol components
    for IVC filters in Illinois; it did not know where Cordis marketed or sold its IVC filters; it
    maintained no offices, agencies, places of business, post office boxes, or telephone listings in
    Illinois; it did not have any interest in any property in Illinois; it did not pay taxes or have
    employees or agents who resided in Illinois; and it did not engage in the direct solicitation of
    business or directly advertise any goods or services in Illinois. Confluent acknowledged that it did
    “sell a very small amount of its products in Illinois” but insisted both that “none of th[o]se products
    [were] related to the IVC filters at issue in this litigation” and that sales of those products in Illinois
    represented only a de minimis amount (less than 0.05%) of its total sales.
    ¶ 11    Confluent attached to its motion the affidavit of its plant controller Jorge Kau, who attested
    to all of the above factual information. The only discrepancy between the facts as presented in
    Confluent’s motion and Mr. Kau’s affidavit was that Mr. Kau said that Confluent’s nitinol-product
    sales in Illinois made up 0.5% of its total sales, rather than 0.05%.
    ¶ 12    During a September 24, 2019, hearing in the circuit court, the parties discussed Confluent’s
    proposed stipulation that, during the time Confluent had manufactured the nitinol component for
    use in Cordis’s OptEase filters, it “was generally aware that Cordis was selling the IVC filters in
    the United States” but “was not aware of the specific states into which Cordis sold its IVC filters,
    including whether Cordis sold its IVC filters in Illinois.” At oral argument in this court there
    appeared to be some dispute about whether this had formally been stipulated to. Having reviewed
    -4-
    No. 1-21-0032
    the complete transcript of the hearing, it appears to us that Ms. Harding’s counsel in fact agreed to
    this statement. The stipulation further stated that Confluent manufactured its component parts in
    California and shipped them to Juarez and that, “[f]rom there, any decision on the ultimate
    destination of the IVC filters was Cordis’[s].” The parties agreed that Confluent had “never had
    control over the ultimate destinations of the IVC filters.”
    ¶ 13   In her response to the motion to dismiss, Ms. Harding insisted that she had established a
    prima facie basis for the court to exercise jurisdiction over Confluent. Ms. Harding relied on the
    following specific facts: (1) her OptEase filter was implanted in an Illinois hospital, (2) the filter
    incorporated a component part that was manufactured by Confluent, (3) though Confluent did not
    specifically know that Cordis sold IVC filters in Illinois, it did know that Cordis sold them
    generally in the United States, and (4) throughout the time relevant to her cause of action,
    Confluent “systematically and consistently engaged in the business of selling nitinol products to
    companies located in Illinois.” In support of her motion, Ms. Harding attached portions of her
    medical records.
    ¶ 14   Ms. Harding also attached interrogatory responses from Confluent stating that its gross
    sales of raw nitinol materials and nitinol components shipped to Illinois were $415,146 in 2009;
    $469,531 in 2010; $276,658 in 2011; $61,261 in 2012; $143,735 in 2013; $263,510 in 2014;
    $132,606 in 2015; $226,047 in 2016, and $101,109 in 2018. Confluent also explained that it did
    not know how all of its Illinois customers used the nitinol once it was shipped, so it could not say
    exactly what percentage was used for medical devices. Confluent was aware, however, that at least
    two of its Illinois customers used Confluent’s raw nitinol materials or nitinol components for
    medical devices and that “[s]ales to those customers accounted for approximately 59% of
    Confluent’s gross sales of raw nitinol materials and/or nitinol components shipped to Illinois
    -5-
    No. 1-21-0032
    between 2011 and 2017.”
    ¶ 15   In support of its motion to dismiss, Confluent attached two affidavits of Tom Duerig, its
    founder and chief technology officer. In the first affidavit, Mr. Duerig stated that, in March 2009,
    Confluent, which was then called NDCI, agreed to supply Cordis with the nitinol components for
    its IVC filters. According to Mr. Duerig, Confluent was bound by Cordis’s specifications for the
    component parts for the IVC filters. Mr. Duerig also attested that he never received “any
    information as to where the IVC filters were sold, including whether they were sold in Illinois.”
    ¶ 16   In the second affidavit, Mr. Duerig stated that he served on Cordis’s management board
    for a time while he was employed there but “d[id] not recall being informed or made aware of the
    particular states or countries in which the Cordis IVC filters were sold, although [he] was generally
    aware that the Cordis IVC filters were sold in the United States and Europe.” Mr. Duerig further
    maintained that at the present time, in his role as president of Confluent, he still did not
    “specifically know where the Cordis IVC filters [were] ultimately marketed, distributed, or sold.”
    ¶ 17   The circuit court denied Confluent’s motion to dismiss. In its written order, the court
    largely relied on our supreme court’s decision in Russell v. SNFA, 
    2013 IL 113909
    . Comparing
    the business relationship in Russell to the one between Confluent and Cordis, the circuit court
    found that Cordis acted as a distributor for the nitinol components manufactured by Confluent.
    The court also found that Confluent benefited from the “laws, infrastructure, and business climate”
    of Illinois because, in addition to manufacturing nitinol component parts for Cordis, Confluent
    also “sold nitinol products to Illinois customers that amounted to 59% of its gross sales of nitinol
    products between 2011 and 2017.”
    ¶ 18   The circuit court found that “Confluent purposefully directed its activities at the State of
    Illinois and the cause of action arose out of or relates to Confluent’s contacts with the state of
    -6-
    No. 1-21-0032
    Illinois.” The circuit court concluded that Cordis was the distributor for Confluent, Confluent knew
    its products were being sold in Illinois, and it was reasonable to require Confluent to defend itself
    in Illinois.
    ¶ 19                                     II. JURISDICTION
    ¶ 20    The circuit court denied Confluent’s motion to dismiss on December 14, 2020, and
    Confluent timely filed a petition for leave to appeal to this court on January 13, 2021. We granted
    that petition on February 24, 2021. Accordingly, we have jurisdiction pursuant to Illinois Supreme
    Court Rule 306(a)(3) (eff. Oct. 1, 2020), governing permissive appeals from the circuit court’s
    denial of a motion to dismiss on grounds that the circuit court lacks personal jurisdiction.
    ¶ 21                                      III. ANALYSIS
    ¶ 22    Section 2-209 of the Code, also referred to as the Illinois long-arm statute, enumerates
    certain acts that will allow Illinois courts to exercise personal jurisdiction over a nonresident
    defendant. 735 ILCS 5/2-209 (West 2020). As relevant here, subsection (c) of the statute also
    permits the exercise of personal jurisdiction over a nonresident defendant “on any other basis now
    or hereafter permitted by the Illinois Constitution and the Constitution of the United States.” 
    Id.
    § 2-209(c). “When subsection (c) is invoked, we assess whether the nonresident defendant[’s]
    contacts with Illinois suffice to satisfy both federal and Illinois due process.” Rios v. Bayer Corp.,
    
    2020 IL 125020
    , ¶ 17. Confluent does not argue that the Illinois Constitution requires any greater
    restraints on the exercise of jurisdiction than the federal constitution, so we need only consider
    federal constitutional principles. 
    Id. ¶ 23
        Ms. Harding, as the plaintiff, had the burden to “establish a prima facie basis for exercising
    personal jurisdiction over a nonresident defendant.” 
    Id. ¶ 16
    . “A plaintiff’s prima facie case may
    be rebutted where a defendant presents uncontradicted evidence that defeats jurisdiction.” Sabados
    -7-
    No. 1-21-0032
    v. Planned Parenthood of Greater Indiana, 
    378 Ill. App. 3d 243
    , 246 (2007). Where, as here, the
    circuit court found that the plaintiff met that burden “solely based upon documentary evidence,
    review is conducted de novo.” 
    Id.
     And in this case, we find that Ms. Harding established that
    Confluent had sufficient minimum contacts to allow Illinois to exercise personal jurisdiction over
    it and that Confluent has failed to present any uncontradicted evidence rebutting that conclusion.
    ¶ 24                                  A. Minimum Contacts
    ¶ 25   The threshold issue in a personal jurisdiction challenge in Illinois is “the ‘minimum
    contacts’ test.” Russell, 
    2013 IL 113909
    , ¶ 36. The contacts necessary to satisfy this test will
    depend on whether general or specific personal jurisdiction is being asserted. 
    Id.
     General
    jurisdiction exists where a corporate defendant “has engaged in continuous and substantial
    business activity within the forum.” 
    Id.
     Specific jurisdiction, which is what Ms. Harding has
    alleged exists here, requires a showing that (1) “the defendant purposefully directed its activities
    at the forum state” and (2) “the cause of action arose out of or relates to the defendant’s contacts
    with the forum state.” 
    Id. ¶ 40
    .
    ¶ 26   One avenue to specific jurisdiction is the “stream-of-commerce theory,” first recognized
    by the United States Supreme Court in World-Wide Volkswagen Corp. v. Woodsen, 
    444 U.S. 286
    (1980). In that case, the Supreme Court held that “[a] forum State does not exceed its powers under
    the Due Process Clause if it asserts personal jurisdiction over a corporation that delivers its
    products into the stream of commerce with the expectation that they will be purchased by
    consumers in the forum State.” 
    Id. at 297-98
    . The parties agree that the relevant inquiry in this
    case is whether the stream-of-commerce theory applies.
    ¶ 27   Our supreme court in Russell, after tracing the history of this theory in the United States
    Supreme Court, offered the following three observations: (1) the United States Supreme Court
    -8-
    No. 1-21-0032
    “unanimously endorsed the continued validity of the stream-of-commerce theory from World-
    Wide Volkswagen to establish specific personal jurisdiction,” but did not settle precisely how that
    theory would be applied; (2) according to a “clear majority of the Court,” “specific jurisdiction
    should not be exercised based on a single sale in a forum, even when a manufacturer or producer
    ‘knows or reasonably should know that its products are distributed through a nationwide
    distribution system that might lead to those products being sold’ ” in the forum state; and (3) only
    a minority of the United States Supreme Court “believes that a broader stream-of-commerce theory
    should be applied to adapt to modern globalized commerce.” (Emphases in original.) Russell, 
    2013 IL 113909
    , ¶¶ 67-69.
    ¶ 28    With these concepts in mind, our supreme court in Russell found that Illinois courts had
    personal jurisdiction over a nonresident defendant based on the stream-of-commerce theory. The
    facts present in Russell, which are very similar to the facts in this case, demonstrated to our
    supreme court, to an extent sufficient to satisfy any due process concerns, that the defendant
    purposefully directed its activities to Illinois and the plaintiff’s claim arose out of those activities.
    ¶ 29    SNFA, the nonresident defendant in Russell, was a French corporation that custom
    manufactured bearings for the aerospace industry and tail-rotor bearings for helicopters made by
    the Italian manufacturer, Agusta. Those helicopters were then distributed internationally by
    Agusta’s American subsidiary, AAC. 
    Id. ¶¶ 10-12
    . The evidence in that case showed that the
    nonresident defendant did not have specific direct knowledge that the finished products were being
    sold in Illinois. 
    Id. ¶¶ 13, 19
    . Our supreme court nevertheless found that the defendant had
    purposefully availed itself of the privileges of conducting activities in Illinois and thereby directed
    its activities to this state. 
    Id. ¶ 80
    .
    ¶ 30    The court first determined that Agusta and AAC “effectively operated as an American
    -9-
    No. 1-21-0032
    distributor” for SNFA’s custom bearings. 
    Id. ¶ 72
    . SNFA custom manufactured bearings
    specifically for Agusta, which were then incorporated into helicopters that were sold
    internationally. Our supreme court emphasized that “the sole market for [the] defendant’s bearings
    of this type would be Agusta or an owner of an Agusta helicopter that needed to replace those
    bearings” and “the only way that [the] defendant’s product *** would ever reach the final
    consumer, including consumers in the United States and Illinois, was through Agusta and its
    American distributor AAC.” (Emphases in original.) 
    Id. ¶ 73
    .
    ¶ 31   In addition to selling custom-made helicopter tail bearings to Agusta, SNFA manufactured
    and sold different bearings for airplanes and fixed-wing aircraft to several other companies,
    including Hamilton Sundstrand, it maintained a business relationship with that company in
    Rockford, Illinois, and one of its employees had made three trips to the Rockford location, at least
    one of which was an attempt to solicit more business. 
    Id. ¶¶ 14-15, 80
    . This was, our supreme
    court found, “additional ‘purposefully directed conduct’ ” or the “ ‘something more’ ” required
    under even a narrow reading of the stream-of-commerce theory. 
    Id. ¶ 80
    .
    ¶ 32   Our supreme court also found that this additional, purposefully directed conduct was
    sufficiently related to the plaintiff’s claim in Russell, such that it should be considered part of the
    defendant’s necessary minimum contacts with the state. As the Russell court noted, “several courts
    ha[d] determined that the applicable standard” for whether a plaintiff’s claims arise from or relate
    to the defendant’s contacts with the forum “is lenient or flexible.” 
    Id. ¶ 83
    . The court thus rejected
    SNFA’s “proposed distinction between subcategories of its primary product, custom-made
    aerospace bearings” as “too restrictive and narrow.” 
    Id. ¶ 84
    . Instead, the court considered the
    totality of the contacts with Illinois that were related to SNFA’s “general product line of custom-
    made bearings.” 
    Id.
    - 10 -
    No. 1-21-0032
    ¶ 33   As noted above, in our view, the jurisdictional issue here is very similar to the one before
    our supreme court in Russell. As in Russell, Confluent has what is effectively a distributor
    relationship with Cordis. Confluent custom manufactures the nitinol component parts for the IVC
    filter at issue specifically for Cordis, based on a design and specifications supplied by Cordis.
    Cordis, in turn, incorporates Confluent’s component parts into the OptEase filter. Confluent knew
    that the OptEase filters would be sold throughout the United States. The sole market for
    Confluent’s nitinol components for the OptEase filters was through Cordis’s nationwide sales and
    the only way Confluent’s custom-made nitinol components for the OptEase filters would ever
    reach the final consumer in Illinois, or anywhere else, was through Cordis.
    ¶ 34   Confluent argues that this case is different than Russell and that there is no distributor
    relationship because it only sold component parts to Cordis, whereas the defendant in Russell also
    sold replacement parts, through the helicopter manufacturer, to the customers who had purchased
    helicopters. We agree with Ms. Harding that this is not a meaningful distinction. As in Russell,
    Confluent made a custom-designed component part that was an integral and inseparable part of a
    finished product that could only reach the consumers through another company—here Cordis—
    and that meant that Cordis was in effect a distributor for Confluent in terms of placing its product
    into the stream of commerce.
    ¶ 35   We reject Confluent’s hyperbolic concern that calling Cordis a distributor means that “any
    manufacturer would become the distributor for any number of component part suppliers.” There
    is an important distinction, one that the circuit court recognized here and that our supreme court
    recognized in Russell, between the sale of standardized component parts having many useful
    applications, such as ordinary nuts and bolts, and the purposeful availment by the manufacturer of
    a highly specialized component part of a distributor’s exclusive network of nationwide marketing
    - 11 -
    No. 1-21-0032
    and sales. Here, Confluent manufactured a nitinol filter that could only enter the stream of
    commerce through the marketing efforts of Cordis.
    ¶ 36    And here there was also the “additional ‘purposefully directed conduct’ ” by Confluent or
    the “something more” that the Russell court highlighted in its analysis—namely, Confluent’s direct
    Illinois sales of raw nitinol and nitinol components and, in particular, the portion of those sales
    that were used for other medical devices.
    ¶ 37    Confluent emphasizes the fact that the circuit court in this case misstated the facts when it
    said that Confluent “sold nitinol products to Illinois customers that amounted to 59% of its gross
    sales of nitinol products between 2011 and 2017.” In fact, the evidence in the record was that 59%
    represented the percentage of Illinois sales to the two customers who were known by Confluent to
    use the nitinol products for medical devices. Thus, as Confluent points out in its brief, the 59%
    was “a subset of the ‘less than 0.5%’of Confluent sales in Illinois.’ ” (Emphasis in original.)
    However, Confluent does not dispute that this 0.5% totaled over $2 million in sales between 2011
    and 2017. Thus, even with the miscalculation, it is clear there were a significant number of direct
    sales by Confluent of nitinol products used for medical devices in Illinois, in addition to the Cordis
    sales of the OptEase filter in this state.
    ¶ 38    As in Russell, these additional direct sales also “relate to” the controversy that Ms. Harding
    seeks to bring before an Illinois court and are part of the calculus as to whether Illinois courts have
    specific jurisdiction over this controversy. As in Russell, distinguishing between nitinol use in the
    OptEase filter and in these other medical devices would be “too restrictive and narrow” for a
    jurisdictional inquiry. Confluent’s direct contacts with Illinois customers are sufficiently related
    to Ms. Harding’s claims in this case to be relied on as additional support for specific jurisdiction.
    ¶ 39    In short, Confluent’s national distribution, through Cordis, of the custom-made nitinol
    - 12 -
    No. 1-21-0032
    component of the OptEase filter, paired with Confluent’s not-insignificant sales of nitinol directly
    to Illinois customers for use in medical devices, are sufficient minimum contacts that are related
    enough to this lawsuit such that Illinois courts have specific personal jurisdiction over Confluent
    for these claims.
    ¶ 40    Confluent relies on a variety of cases to argue that the requisite relationship between its
    contacts with Illinois and Ms. Harding’s claims is not present here: In its brief, Confluent relied
    heavily on Wiles v. Morita Iron Works Co., 
    125 Ill. 2d 144
     (1988), Bristol-Myers Squibb Co. v.
    Superior Court of California, 582 U.S. ___, 
    137 S. Ct. 1773
     (2017), and Ford Motor Co. v.
    Montana Eighth Judicial District Court, 592 U.S. ___, 
    141 S. Ct. 1017
     (2021). At oral argument,
    Confluent also particularly stressed the applicability of Young v. Ford Motor Co., 
    2017 IL App (4th) 170177
    . These cases are all distinguishable, and none of them alter our analysis.
    ¶ 41    In Wiles, a Japanese corporate defendant manufactured machines that were delivered to the
    plaintiff’s New Jersey employer in Japan, who then delivered the offending machine to Illinois,
    where the plaintiff was injured. Wiles, 
    125 Ill. 2d at 147
    . The Japanese defendant was not aware
    of the employer’s actions that led to its machine ending up in Illinois. It did not own or operate
    any manufacturing plant or other business in Illinois, and it had no other connections to Illinois.
    
    Id. at 147-48, 159-61
    .
    ¶ 42    Confluent cites Wiles for our supreme court’s observation that “purposeful availment” for
    jurisdictional purposes requires “at a minimum” that a defendant have knowledge that its product
    is marketed in Illinois. (Emphasis in original.) 
    Id. at 160
    . But the court clarified this limitation
    further in Russell, where it relied on this language to hold that “the unilateral action of a third party
    does not satisfy the minimum contacts standard.” Russell, 
    2013 IL 113909
    , ¶¶ 55-57. As the court
    in Russell ruled, the fact that the defendant does not have actual knowledge that the offending
    - 13 -
    No. 1-21-0032
    product is specifically being sold in Illinois is simply not dispositive. 
    Id. ¶¶ 13, 19, 85
    .
    ¶ 43    In Bristol-Myers, the United States Supreme Court found that California could not exercise
    personal jurisdiction over a nonresident defendant because there were nonresident plaintiffs
    involved in the suit and there was not “any adequate link between the State and the nonresidents’
    claims.” 582 U.S. at ___, 137 S. Ct. at 1781. As the Supreme Court explained, specific jurisdiction
    was lacking where the relevant plaintiffs were not only nonresidents themselves and did not claim
    to have suffered harm in the forum state, but “[i]n addition, *** all the conduct giving rise to [their]
    claims occurred elsewhere.” Id. at 1782. In contrast, Ms. Harding was an Illinois resident injured
    in Illinois, and Confluent had the connections to this state that we have outlined above.
    ¶ 44    In Ford, the Supreme Court concluded that two different states could exercise personal
    jurisdiction over Ford Motor Company because, although the two specific vehicles at issue were
    not themselves sold by Ford in the forum states, Ford did market and sell the same two models in
    those states. 592 U.S. at ___, 141 S. Ct. at 1028-29. Confluent argues that Ford thus “stands for
    the proposition that the plaintiff need not show that the defendant sold the specific unit of the
    accident-causing product in the forum state, provided it marketed and sold other units of that same
    product in the forum state.” (Emphases in original.) We agree. But nothing in Ford suggests that
    the only way to demonstrate that a defendant has minimum contacts with a forum state is through
    sales of the injurious product. Rather, as in this case, jurisdiction can be based on a combination
    of the sales of the offending product and other sales of similar products that, in total, provide
    evidence that the defendant “purposefully directed its activities” at the forum state and that the
    plaintiff’s claim sufficiently relates to the defendant’s varied contacts with the forum state.
    ¶ 45    In Young, as in this case and in Russell, it appears that the company that sold the offending
    product in Illinois was acting as a distributor for a custom-made product manufactured by the out-
    - 14 -
    No. 1-21-0032
    of-state defendant. 
    2017 IL App (4th) 170177
    , ¶ 13. This was a key part of the Russell decision
    that the Fourth District in Young did not address when it distinguished Russell and affirmed the
    circuit court’s finding that there was no personal jurisdiction over the Chinese defendant in that
    case. 
    Id. ¶ 44
    . First, we are of course not bound by the holding in Young. People v. Leavitt, 
    2014 IL App (1st) 121323
    , ¶ 48 (noting that “[w]e are only obliged to follow the decisions of the
    Supreme Court of Illinois and of the United States Supreme Court”). More importantly, the Young
    case is different from this one. In Young, the court stressed that the Chinese defendant had “no
    direct product sales with customers based in Illinois.” Young, 
    2017 IL App (4th) 170177
    , ¶ 9. In
    contrast, here, Confluent engaged in direct product sales of nitinol products for medical devices in
    Illinois. Thus, there is no conflict between our decision in this case and that of the court in Young.
    ¶ 46                             B. Illinois Is a Reasonable Forum
    ¶ 47   The Russell court separately conducted a reasonableness inquiry, after finding the requisite
    minimum contacts, to ensure that it was reasonable to require the defendant to litigate in Illinois.
    Russell, 
    2013 IL 113909
    , ¶¶ 87-91. According to our supreme court in that case,
    “[t]he factors to consider when deciding reasonableness include: (1) the burden imposed
    on the defendant by requiring it to litigate in a foreign forum; (2) the forum state’s interest
    in resolving the dispute; (3) the plaintiff’s interest in obtaining relief; and (4) the interests
    of the other affected forums in the efficient judicial resolution of the dispute and
    advancement of substantive social policies.” 
    Id. ¶ 87
    .
    ¶ 48   Confluent has not put forward any evidence of a burden that it would have in litigating in
    Illinois. Indeed, the only basis on which Confluent suggests that it is unreasonable to require it to
    litigate here is that it lacks the requisite minimum contacts with this state, an argument that we
    have already rejected.
    - 15 -
    No. 1-21-0032
    ¶ 49   As to the other relevant factors, the circuit court observed:
    “Here, Illinois has a strong interest in resolving litigation from the alleged failure
    of a medical device causing serious and permanent injury to an Illinois resident. Other than
    Illinois and California there does not appear to be any other forum that would have an
    interest in the controversy. Because the incident occurred in Illinois and involved an
    individual living in Illinois, Illinois has a substantial interest in this dispute that implicates
    the societal concerns of product liability and the safe medical care, issues that are clearly
    of interest to the citizens of Illinois.”
    We agree with the circuit court’s observations, none of which are disputed by Confluent. In short,
    requiring Confluent to defend itself in Illinois is reasonable.
    ¶ 50                                     IV. CONCLUSION
    ¶ 51   Confluent had sufficient minimum contacts with Illinois, such that there is no due process
    violation in requiring it to defend itself in Illinois courts in this lawsuit. It is also reasonable to
    require Confluent to defend itself in this state in this case. The circuit court correctly found that
    Illinois may exercise specific personal jurisdiction over Confluent.
    ¶ 52   Affirmed.
    - 16 -
    No. 1-21-0032
    No. 1-21-0032
    Cite as:                 Harding v. Cordis Corp., 
    2021 IL App (1st) 210032
    Decision Under Review:   Appeal from the Circuit Court of Cook County, No. 17-L-8306;
    the Hon. Gerald Cleary, Judge, presiding.
    Attorneys                H. Patrick Morris, Garrett L. Boehm Jr., and David F. Fanning,
    for                      of Johnson & Bell, Ltd., of Chicago, for appellant.
    Appellant:
    Attorneys                David R. Nordwall, of Law Office of David R. Nordwall, LLC,
    for                      of Chicago, for appellee.
    Appellee:
    - 17 -
    

Document Info

Docket Number: 1-21-0032

Citation Numbers: 2021 IL App (1st) 210032

Filed Date: 12/3/2021

Precedential Status: Precedential

Modified Date: 12/3/2021